Off-Label Use Of Stryker Wingspan Stent Could Pose Serious Risks: US FDA
Executive Summary
The agency issued a recent safety alert against off-label use of Stryker’s Wingspan Stent. Based on a postmarket study, regulators found higher rates of stroke and death in patients who were treated with the stent for other than its approved indication.
You may also be interested in...
ISC 2018: WEAVE Post-Market Data Boost Stryker's Wingspan Brain Stent
Stryker's Wingspan intracranial stent, the subject of controversy several years ago when a post-market trial showed an unexpectedly high risk of adverse events with the device, can be deployed effectively with minimal risk in the specific patient population indicated on its label, results of the WEAVE study show.
FDA Narrows Indication For Stryker’s Wingspan Intracranial Stent
Agency restricts use of the device to a select patient population with severe intracranial stenosis and recurrent stroke after reviewing studies indicating the device could actually lead to increased rates of stroke and death.
News We’re Watching: Lung Preservation System Goes National, De Novo For MMI, Brazil’s ANVISA To Recognize Overseas Approvals
This week, Paragonix announced that its BAROguard lung preservation system is now available throughout the US; Brazil planned to leverage some foreign device approvals; Medical Microinstruments’ Symani Surgical System won de novo clearance; and the FDA updated its safety warnings for Essure and certain plastic syringes.